Van ECK Associates Corp Buys 475 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Van ECK Associates Corp boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,539 shares of the biotechnology company’s stock after acquiring an additional 475 shares during the quarter. Van ECK Associates Corp’s holdings in United Therapeutics were worth $2,421,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in UTHR. Norges Bank bought a new stake in United Therapeutics during the fourth quarter worth approximately $100,519,000. Avidity Partners Management LP bought a new position in shares of United Therapeutics during the fourth quarter valued at approximately $52,158,000. Comerica Bank grew its stake in shares of United Therapeutics by 2,697.2% during the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after buying an additional 150,989 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of United Therapeutics by 309.7% during the fourth quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock valued at $29,501,000 after buying an additional 101,419 shares during the last quarter. Finally, TD Asset Management Inc grew its stake in shares of United Therapeutics by 1,066.4% during the fourth quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock valued at $18,240,000 after buying an additional 75,839 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $40,622.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $40,622.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 2,240 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the sale, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The disclosure for this sale can be found here. Insiders sold a total of 112,544 shares of company stock worth $29,811,740 over the last 90 days. Company insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 1.1 %

United Therapeutics stock opened at $314.56 on Friday. The business has a fifty day moving average of $282.72 and a two-hundred day moving average of $246.34. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The firm has a market cap of $13.95 billion, a P/E ratio of 14.87, a P/E/G ratio of 1.38 and a beta of 0.55. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $325.00.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics’s revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.86 earnings per share. On average, analysts forecast that United Therapeutics Co. will post 24.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on UTHR. JPMorgan Chase & Co. upped their target price on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research note on Thursday, May 2nd. The Goldman Sachs Group upped their target price on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Wells Fargo & Company increased their price objective on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Finally, Oppenheimer increased their price objective on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.